Pharmaceuticals News and Research

RSS

Medivir initiates TMC649128 phase Ib trial in chronic hepatitis C

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, today announces the start of a phase Ib clinical trial with TMC649128 intended for the treatment of chronic hepatitis C virus (HCV) infection.

22 Jun 2011

CEL-SCI announces results from Multikine Phase II trial on head and neck cancer

CEL-SCI Corporation announced today data from its Phase II clinical studies which showed that its lead drug Multikine was able to lower cholesterol in studies involving 120 head and neck cancer patients.

22 Jun 2011

Caffeinated coffee boosts blood GCSF levels, protects against Alzheimer's

A yet unidentified component of coffee interacts with the beverage's caffeine, which could be a surprising reason why daily coffee intake protects against Alzheimer's disease.

22 Jun 2011

CSL Biotherapies statement on FDA warning letter

Today the US Food and Drug Administration (FDA) published a Warning Letter issued by its Office of Compliance and Biologics Quality to CSL Biotherapies, a division of CSL Limited. The FDA regulates the manufacture, marketing and distribution of CSL Biotherapies’ influenza vaccine, Afluria®, in the US market.

21 Jun 2011

TESARO secures $101M in Series B financing

TESARO, Inc., an oncology-focused biopharmaceutical company, today announced that it has secured $101 million in a Series B financing to advance and expand the Company's cancer product portfolio.

21 Jun 2011

EC grants marketing authorization to BYDUREON for treatment of type 2 diabetes

Eli Lilly and Company, together with Amylin Pharmaceuticals, Inc. and Alkermes, Inc., announced today that the European Commission has granted marketing authorization to BYDUREON.

21 Jun 2011

NextGen launches first CSF multiplex protein assay for detecting CNS diseases

NextGen Group plc is pleased to announce that its US-subsidiary NextGen Sciences Inc, a leader in biomarker discovery, measurement and qualification, has launched its first cerebrospinal fluid (CSF) multiple protein assay, csfdiscovery43, for central nervous system (CNS) biomarker discovery and qualification.

21 Jun 2011

IPS examines access to treatment for drug-resistant TB

"Access to treatment for drug-resistant tuberculosis remains compromised, especially in developing countries, because too few pharmaceutical companies manufacture quality-assured drugs," Inter Press Service reports in an article examining how a lack of competition and a working mechanism to keep prices low "has led to skyrocketing prices."

21 Jun 2011

New anti-abuse formulation of painkiller Oxycodone

It has come to health officials’ attention nationwide that there is a serious rise of abuse of painkillers, especially opioids. Federal officials recently stepped up plans to monitor frequent prescribers and users.

21 Jun 2011

Lorcaserin Phase 3 trial data on type 2 diabetes to be presented at ADA 2011

Arena Pharmaceuticals, Inc. and Eisai Inc. announced today that lorcaserin data from the Phase 3 BLOOM-DM trial will be presented in poster sessions at the American Diabetes Association's (ADA) 71st Scientific Sessions in San Diego, California.

21 Jun 2011

Halozyme to present three data on Ultrafast Insulin programs at ADA 2011

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced three upcoming data presentations for it Ultrafast Insulin programs at the American Diabetes Association (ADA) 71st Scientific Sessions taking place June 24-28, 2011 at the San Diego Convention Center.

21 Jun 2011

U.S. FDA approves generic Levaquin for treatment of bacterial infections

The U.S. Food and Drug Administration today approved the first generic versions of Levaquin, an antibiotic approved to treat certain infections in people ages 18 and older.

21 Jun 2011

Rheonix, Mayo Clinic partner for genotyping test to assist warfarin sensitivity

Mayo Clinic today announced that it has reached an agreement with Rheonix, Inc. to collaborate on the performance of a genotyping test for warfarin sensitivity in clinical and research settings.

21 Jun 2011

Public-private partnerships leading to successes in HIV treatment and prevention

The recent achievements in studies looking at treatment as prevention "were only made possible by the partnership between publicly funded scientists and private drug companies," Ward Cates, president of research at FHI; Salim Abdool Karim, director of the Centre for the AIDS Program of Research in South Africa; and Myron Cohen, director of the UNC Division of Infectious Disease and the UNC Institute for Global Health and Infectious Disease, write in an opinion piece in the Huffington Post.

21 Jun 2011

Sentrx, TransPerfect collaborate to offer Trial Interactive Portal Technology

TransPerfect and Sentrx have announced a collaboration involving TransPerfect's Trial Interactive Portal Technology, which will streamline end-to-end global drug safety capabilities in both clinical and post-marketing event management.

21 Jun 2011

Amylin to present data on investigational diabetes drug candidates at ADA annual meeting

Amylin Pharmaceuticals, Inc. today announced that the Company will present data for its two first-in-class diabetes drugs, BYETTA injection and SYMLIN injection, and its investigational diabetes drug candidates BYDUREON and exenatide once monthly at the 71st Scientific Sessions of the American Diabetes Association (ADA) being held in San Diego, CA from June 24 to June 28.

21 Jun 2011

Mayo Clinic announces collaboration on genotyping test for Warfarin sensitivity

Mayo Clinic today announced that it has reached an agreement with Rheonix, Inc. to collaborate on the performance of a genotyping test for warfarin sensitivity in clinical and research settings. The genotyping test will be available for all patients of Mayo Clinic and is the subject of ongoing research for improved anticoagulation therapy. Additionally, the test will be offered through Mayo Clinic’s reference laboratory, Mayo Medical Laboratories, to clients throughout the world.

20 Jun 2011

Endo acquires American Medical Systems for $2.9 billion in cash

Endo Pharmaceuticals announced today the completion of its acquisition of American Medical Systems, Inc. (AMS). Endo announced on April 11, 2011, that it entered into a definitive agreement to acquire AMS, a leading provider of world-class devices and therapies for male and female pelvic health, for approximately $2.9 billion in cash.

20 Jun 2011

FDA's new strategy calls for coalitions of international regulators, increased data sharing

The U.S. Food and Drug Administration today unveiled a new strategy to meet the challenges posed by rapidly rising imports of FDA-regulated products and a complex global supply chain in a report called the "Pathway to Global Product Safety and Quality."

20 Jun 2011

Derma Sciences to raise $29M through private placement

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today announced it has entered into definitive agreements with select institutional investors to raise gross proceeds of approximately $29 million.

20 Jun 2011